BI-RADS 3类病变的影像与活检结局:大型队列的随访依从性、活检率及恶性率
该研究回顾性分析了2013至2015年间2075例女性的2319个BI-RADS 3类病变,活检率为7.5%,恶性率仅0.6%(5/783);所有癌症均在基线或6个月随访时通过形态变化或病变增长发现,但患者随访依从性低,仅16.7%完成全部随访。
要点
- BI-RADS 3类病变恶性率极低(0.6%),多数活检由患者/医生意愿驱动而非影像指征。
- 所有癌症均在基线或6个月随访时发现,提示首次6个月随访至关重要。
- 随访依从性差,仅16.7%完成全部随访,应鼓励影像随访而非 upfront 活检。
核心结论
- BI-RADS 3类病变的活检率显著高于恶性率,所有癌症均在基线或首次随访时被识别。
- 患者随访依从性低,应鼓励影像随访尤其是首次6个月随访,而非 upfront 活检。
研究设计与样本
- 回顾性队列研究,纳入2013至2015年间2075例女性的2319个BI-RADS 3类病变(乳腺X线和/或超声),以至少2年随访或活检病理为终点。
关键影像表现/征象
- 可触及(P < .001)和较大病变(中位1.4 vs 1.0 cm,P < .001)以及年龄<40岁女性(15.2% vs 4.8%,P < .001)更可能接受活检。
- 多数活检由患者/医生意愿驱动(64.5%,P < .001)。
- 5例癌症中3例因形态变化、2例因病变增长而活检,均在0-5个月(n=1)或5-9个月(n=4)发现。
诊断标准与关键数值
- BI-RADS 3类病变定义为可能良性,建议短期随访。
- 恶性率0.6%(5/783有终点病变),活检率7.5%(173/2319)。
- 随访完成率:全部随访16.7%(310/1855),两次26.1%(482/1855),一次26.5%(489/1855),无随访30.6%(565/1855)。
临床应用与阅片要点
- 对BI-RADS 3类病变应优先推荐6个月影像随访,避免不必要的 upfront 活检。
- 报告时应关注病变大小、可触及性及患者年龄(<40岁)等增加活检概率的因素。
- 随访中注意形态变化和病变增长,这些是发现恶性病变的主要征象。
局限性
- 回顾性研究设计。
- 仅783个病变有可用终点,随访依从性低可能导致结局评估不完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To identify biopsy rates and indications for BI-RADS 3 lesions in a large cohort of patients and compare with follow-up compliance and malignancy outcomes.
METHODS: We retrospectively reviewed all BI-RADS category-3 lesions seen on mammography and/or ultrasound between 2013 and 2015. Patient age, lesion size, follow-up rates at 6-, 12-, and 24-months were collected. Biopsy timing, indication, and outcomes (malignant vs benign) were recorded using at least 2-year follow-up or biopsy pathology as endpoint.
RESULTS: Of 2319 BI-RADS 3 lesions in 2075 women analyzed, biopsy was performed in 173 (7.5%). Most biopsies were performed upfront (99, 57.2%), followed by at 6 (44, 25.4%), 12 (21, 12.1%), and 24-month follow-up (9, 5.2%; P < .001). Palpable (P < .001) and larger (median 1.4 vs 1.0 cm, P < .001) lesions in women <40 years (15.2% vs 4.8%, P < .001) were more likely to undergo biopsy. Most biopsies were prompted by patient/physician desire (64.5%, P < .001). Of 783 lesions with available endpoint, 5 (0.6%) were cancer. All cancers were identified either at presentation (in 0-5 months, n = 1) or 6-month follow-up (in 5-9 months, n = 4) with biopsy prompted by either morphology change (n = 3) or lesion growth (n = 2). Of the 1855 lesions which were expected for follow up, only 310 (16.7%) underwent all follow-ups, while 482 (26.1%) had two, 489 (26.5%) one, and 565 (30.6%) had no follow-up.
CONCLUSIONS: In our cohort, BI-RADS category 3 lesions had significantly higher biopsy rates compared with the small malignancy rate, all of which were identified at baseline or first follow-up. Overall patient follow-up compliance low. Imaging follow-up, especially at first 6-month time point, should be encouraged in BI-RADS 3 lesions, instead of upfront biopsies.
引用
- Polat, Merchant, Hayes, et al. Outcome of Imaging and Biopsy of BI-RADS Category 3 Lesions: Follow-Up Compliance, Biopsy, and Malignancy Rates in a Large Patient Cohort. J Ultrasound Med. 2022. PMID: 36445017. doi:10.1002/jum.16142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。